Substitute Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Information Disclosure Statement

by Applicant

Use several sheets if necessary)

(37 CFR \$1.98(b))

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 11926-015002

Applicant

Vincent P. Stanton, Jr.

Filling Date

September 24, 2001

Group Art Unit

September 24, 2001

MADEMA			U.S. Pate	ent Documents			20.
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
AC	AA	6,015,673	1/18/2000	Gonzalez et al.	435	6	8
	AB	6,074,821	6/13/2000	Rozen et al.	435	6	
	AC	6,130,043	10/10/2000	Billing-Medel et al.	435	6	
	AD	6,218,120	4/17/2001	Rozen et al.	435	6	
	AE						
	AF						
,	AG						¥
	AH						
,	AI						×
	AJ						
	AK						
	AL		*			,	
	AM					*	

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No	
	AN	WO 95/33054	12/7/1995	WIPO	_			
	AO							
	AP		9					
	AQ			-				
	AR							

[Other Documents (include Author, Title, Date, and Place of Publication)					
	Exan	niner	Desig.				
	Initial		ID	Document			
4			AS	Akar et al., "Effect of Metylenetetrahydrofolate Reductase 677 C-T, 1298 A-C, and 1317 T-C on Facotr V" Thrombosis Research 97:163-167, 2000.			
2	•	V	ΑT	Engbersen et al., "Thermolabile 5,10-Methylenetetrahydrofolate Reductase as a Cause of Mild Hyperhomocysteinemia" Am. J. of Human Genet. 56:142-150, 1995.			
3	-1	4c	AU	Frosst et al., "A Candidate Genetic Risk Factor for Vascular Disease: a Common Mutation in Methylenetetrahydrofolate Reductase" Nature Genetics 10:111-113, 1995.			

Examiner Signature

row Kr. Chakoalegrob

Date Considered

12/2/02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute For (Modified)	m PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 11926-015002	Application No. 09/963,333			
	OIP AM	~	n Disclosure Statement by Applicant	Applicant Vincent P. Stanton, Jr.				
	JAN 1 6 2002 (37 CFR §1.98	Š.	veral sheets if necessary)	Filing Date September 24, 2001	Group Art Unit 9			
ther Documents (include Author, Title, Date, and Place of Publication								
Property Design								
	Initial	ID ID	· ·	Document	5 6 5			
14	Initial ID Document AV Goyette et al., "Human Methylenetetrahydrofolate Reductase: Isolation of cDNA Mutation Identification" Nature Genetics 7:195-200, 1994.				n of cDNA, Mapsing and			
ستخد	AW Goyette et al., "Gene Structure of Human and Mouse Methylenetetrahydrofolate Reductase (MTHFR)" Mammalian Genome 9:652-656, 1998.							
-6-	Goyette et al., "Seven Novel Mutations in the Methylenetetrahydrofolate Reductase Gene and Genotype/Phenotype Correlations in Severe Methylenetetrahydrofolate Reductase Deficiency" A J. Hum. Genet. 56:1052-1059, 1995.							
A	AY . Goyette et al., GenBank Accession No U09806, Dec. 6, 1999.							
-6		AZ	Kaneda et al., "Structural and Functional Analysis of the Human Thymidylate Synthase Gene" J. of Biol. Chem. 265:20277-20284, 1990.					
9		AAA ,	Kang et al., "Thermolabile Methylenetetrahydrofolate Reductase: An Inherited Risk Factor for Coronary Artery Disease" Amer. J. Human. Genet. 48:536-545, 1991.					
10	-	ABB .	Van der Put et al., "A Second Common Mutation in the Methelenetetrahydrofolate Reductase Gene: An Additional Risk Factor for Neural-Tube Defects" Am. J. Hum. Genet. 62:1044-1051, 1998.					
4		ACC ,	Van Ede et al., "Methotrexate in Rheumatoid Arthiritis: An Update with Focus on Mechanisms Involved in Toxicity" Seminars in Arthiritis and Rheumatism 27:277-292, 1998.					
4		ADD /	Viel et al., "Loss of Heterozygosity at the 5,10-Methylenetetrahydrofolate Reductase Locus in Human Ovarian Carcinomas" British J. of Cancer 75:1105-1110, 1987.					
-13	-Ae	AEE	Weisberg et al., "A second Genetic Polymorphism in Methylenetetrahydrofolate Reductase (MTHFR) Associate with Decreased Enzyme Activity" Mol. Genet. And Metabolism 64:169-172, 1998.					

Examiner Signature

u kr. Chakrowlash

Date Considered

12/2/02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.